Johnson & Johnson discontinued two CAR-T programs in B cell lymphoma, ending development of JNJ-9530 and JNJ-4496 amid a changing treatment landscape that has rapidly expanded with approvals of newer modalities. The programs had been in Phase 1 and Phase 1/2 trials. J&J said the company is aligning with portfolio priorities and its assessment of the evolving large B-cell lymphoma market, while continuing to support patients enrolled in ongoing trials according to study protocols. J&J previously paid Cellular Biomedicine $245 million for the related CAR-T assets in 2023. The move removes potential future competitive pressure in CD19/CD20 and CD20-directed CAR-T space, while underscoring how quickly clinical success and regulatory approvals can reshape big pharma cell therapy strategies.